Russell Investments Group
OVID icon

Russell Investments Group’s Ovid Therapeutics OVID Stock Holding History

Russell Investments Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9K Buy
+12,220
New +$31.5K ﹤0.01% 3719
2025
Q1 		– Sell
-447
Closed -$417 – 3858
2024
Q4 		$417 Sell
447
-1,317
-75% -$1.47K ﹤0.01% 3628
2024
Q3 		$2.08K Buy
1,764
+166
+10% +$173 ﹤0.01% 3367
2024
Q2 		$1.23K Buy
+1,598
New +$4.45K ﹤0.01% 3413
2023
Q4 		– Sell
-57
Closed -$219 – 3282
2023
Q3 		$219 Buy
+57
New +$205 ﹤0.01% 3487
2023
Q2 		– Sell
-267,459
Closed -$690K – 3511
2023
Q1 		$690K Sell
267,459
-1,256
-0.5% -$2.98K ﹤0.01% 2142
2022
Q4 		$500K Hold
268,715
– – ﹤0.01% 2287
2022
Q3 		$492K Buy
268,715
+847
+0.3% +$1.77K ﹤0.01% 2251
2022
Q2 		$574K Sell
267,868
-8,105
-3% -$19.6K ﹤0.01% 2217
2022
Q1 		$865K Sell
275,973
-30,583
-10% -$96.2K ﹤0.01% 2023
2021
Q4 		$983K Buy
+306,556
New +$1.05M ﹤0.01% 2155
2021
Q2 		– Sell
-104,283
Closed -$419K – 3274
2021
Q1 		$419K Buy
+104,283
New +$346K ﹤0.01% 2594
2019
Q1 		– Sell
-500
Closed -$1K – 2988
2018
Q4 		$1K Buy
+500
New +$2.28K ﹤0.01% 2902

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Russell Investments Group's OVID Position: Q2 2026 in Review

Russell Investments Group opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 12,220 shares worth $32.9K. The stake represents ﹤0.01% of the portfolio and ranks #3719 among its holdings. This is a return to the name: Russell Investments Group previously reported a position in OVID as recently as Q4 2024.

Russell Investments Group first reported a position in OVID in Q4 2018 and has held it in 13 quarters since. The position peaked at $983K in Q4 2021. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Russell Investments Group held 12,220 shares of Ovid Therapeutics worth $32.9K as of Q2 2026.
  • Ovid Therapeutics was a new Russell Investments Group position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3719 holding.
  • Russell Investments Group first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • Russell Investments Group's Ovid Therapeutics position peaked at $983K in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.